Soft Lumps Over the Sacrum: Differential Diagnosis
Soft lumps over the sacrum most commonly represent lipomas (the most frequent soft-tissue tumor), but the differential includes both benign entities (neurogenic tumors, hemangiomas, abscesses, hematomas) and malignant lesions (metastases being most common, followed by primary tumors like chordoma), requiring systematic imaging evaluation starting with radiographs followed by MRI for definitive characterization 1, 2.
Initial Diagnostic Approach
Begin with plain radiographs as the fundamental first step, despite the sacral location 1. While radiographs may seem unrewarding for soft tissue masses, they demonstrate positive findings in 62% of cases, identifying calcifications (27%), bone involvement (22%), or intrinsic fat (11%) 1. Radiographs can reveal:
- Phleboliths (suggesting hemangioma)
- Bone destruction or sclerosis (indicating malignancy or infection)
- Calcification patterns (helpful for narrowing differentials)
For superficial palpable masses, ultrasound is increasingly useful as an initial study, particularly for suspected lipomas, with 94.1% sensitivity and 99% specificity for superficial soft-tissue masses 1. Lipomas show characteristic features: minimal acoustic shadowing, minimal vascularity, and curved echogenic lines within an encapsulated mass 1.
Key Clinical Red Flags
Assess these specific features that distinguish benign from malignant:
- Size >5 cm raises malignancy concern 3
- Deep location (relative to fascia) is worrisome 3
- Firmness greater than surrounding muscle suggests malignancy 3
Critical caveat: Up to 32% of soft-tissue sarcomas present as small, superficial masses, so size alone cannot exclude malignancy 3.
Differential Diagnosis by Frequency
Most Common: Benign Lesions
- Lipomas (most frequent soft-tissue tumor overall) 1
- Neurogenic tumors (schwannoma, neurofibroma) - the paraspinal/sacral region is rich in spinal nerves 4
- Hemangiomas (identifiable by phleboliths on radiograph) 1
Tumor-Like Masses
- Hematomas (consider trauma history) 4
- Abscesses (10/19 nonneoplastic sacral lesions showed nonspecific inflammation) 5
- Extramedullary hematopoiesis (in appropriate clinical context) 4
Malignant Lesions (Less Common but Critical)
In adults, metastases are the most common sacral malignancy 6, 7. Among 91 sacral FNA cases, 77% of malignant tumors were metastatic/secondary 5:
- Colorectal carcinoma (22% of secondary tumors) 5
- Plasmacytic tumors/myeloma (56% of hematologic malignancies) 5
- Other metastases from various primaries
Primary malignant tumors (14% of malignancies in sacral region) 5:
- Chordoma (most common primary malignant sacral tumor, 36% of primary malignancies) 5, 6, 7
- Chondrosarcoma 7
- Ewing's sarcoma (sacral predilection) 2
- Liposarcoma and undifferentiated sarcomas 4
Definitive Imaging Algorithm
If radiographs are non-diagnostic or show concerning features, proceed directly to MRI - this is the definitive modality for soft-tissue mass characterization 1, 2. MRI provides:
- Precise anatomic localization (superficial vs. deep to fascia)
- Tissue characterization (fat, fluid, solid components)
- Assessment of bone involvement
- Evaluation of neural and vascular structures
- Tumor extent for surgical planning
PET/CT is reserved for systemic disease evaluation in myeloma, lymphoproliferative disease, and known metastatic disease 2.
Critical Management Pitfall
The most common diagnostic error is assuming all soft masses are lipomas 3. Physical examination alone correctly identifies lipomas in only 85% of cases 1.
If your institution cannot perform accurate diagnostic studies or definitive treatment, refer to a specialized center BEFORE biopsy 1. Inappropriate biopsy can compromise subsequent surgical management and worsen outcomes.
When to Obtain Tissue Diagnosis
FNA of sacral/presacral lesions has 96% accuracy, 95% sensitivity, and 100% specificity 5. Consider biopsy when:
- Imaging is indeterminate
- Malignancy is suspected based on size/depth/firmness criteria
- Patient has prior malignancy history (62% of sacral lesions occur in this context) 5
- Progressive symptoms or growth
Coordinate biopsy with the treating oncologic surgeon to avoid compromising surgical planes 1.